Mills Kenneth T. 4
4 · REGENXBIO Inc. · Filed Jul 18, 2024
Insider Transaction Report
Form 4
REGENXBIO Inc.RGNX
Mills Kenneth T.
Director
Transactions
- Exercise/Conversion
Stock Options (Right to Buy)
2024-07-17−2,210→ 78,944 totalExercise: $3.76Exp: 2025-05-19→ Common Stock (2,210 underlying) - Exercise/Conversion
Stock Options (Right to Buy)
2024-07-16−200→ 81,154 totalExercise: $3.76Exp: 2025-05-19→ Common Stock (200 underlying) - Sale
Common Stock
2024-07-16$13.76/sh−200$2,752→ 408,035 total - Exercise/Conversion
Common Stock
2024-07-16$3.76/sh+200$752→ 408,235 total - Exercise/Conversion
Common Stock
2024-07-17$3.76/sh+2,210$8,310→ 410,245 total - Sale
Common Stock
2024-07-17$13.77/sh−2,210$30,440→ 408,035 total
Footnotes (3)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan.
- [F2]This transaction was executed in multiple trades at prices ranging from $13.76 to $13.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.